- Home
- GLMD vs VTAK Comparison
GLMD vs VTAK Comparison
Compare GLMD & VTAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLMD
- VTAK
- Stock Information
- Founded
- GLMD 2000
- VTAK 2002
- Country
- GLMD Israel
- VTAK United States
- Employees
- GLMD N/A
- VTAK N/A
- Industry
- GLMD Biotechnology: Pharmaceutical Preparations
- VTAK Medical/Dental Instruments
- Sector
- GLMD Health Care
- VTAK Health Care
- Exchange
- GLMD Nasdaq
- VTAK Nasdaq
- Market Cap
- GLMD 3.0M
- VTAK 3.1M
- IPO Year
- GLMD 2014
- VTAK 2018
- Fundamental
- Price
- GLMD $1.83
- VTAK $0.23
- Analyst Decision
- GLMD Hold
- VTAK
- Analyst Count
- GLMD 1
- VTAK 0
- Target Price
- GLMD N/A
- VTAK N/A
- AVG Volume (30 Days)
- GLMD 353.4K
- VTAK 41.3M
- Earning Date
- GLMD 05-22-2025
- VTAK 08-13-2025
- Dividend Yield
- GLMD N/A
- VTAK N/A
- EPS Growth
- GLMD N/A
- VTAK N/A
- EPS
- GLMD N/A
- VTAK N/A
- Revenue
- GLMD N/A
- VTAK $481,000.00
- Revenue This Year
- GLMD N/A
- VTAK $822.86
- Revenue Next Year
- GLMD N/A
- VTAK $168.42
- P/E Ratio
- GLMD N/A
- VTAK N/A
- Revenue Growth
- GLMD N/A
- VTAK 9.57
- 52 Week Low
- GLMD $1.15
- VTAK $0.16
- 52 Week High
- GLMD $23.80
- VTAK $4.76
- Technical
- Relative Strength Index (RSI)
- GLMD 60.37
- VTAK 44.77
- Support Level
- GLMD $1.74
- VTAK $0.22
- Resistance Level
- GLMD $1.91
- VTAK $0.28
- Average True Range (ATR)
- GLMD 0.12
- VTAK 0.04
- MACD
- GLMD -0.00
- VTAK -0.01
- Stochastic Oscillator
- GLMD 71.95
- VTAK 6.09
About GLMD Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development of Aramchol. exclusively on developing Aramchol for the treatment of liver disease and were previously developing Aramchol for primary sclerosing cholangitis, PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of NASH and fibrosis. The company is currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis.
About VTAK Catheter Precision Inc.
Catheter Precision Inc is engaged in design, manufacture and sale of new and innovative medical technologies primarily focused in the field of cardiac electrophysiology, or EP. The Company's primary product is the View into Ventricular Onset System (VIVO or VIVO System), which is a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. The VIVO system has achieved a CE Mark allowing it to be commercialized in the European Union and has been placed at several hospitals in Europe. Its newest product, the Surgical Vessel Closing Pressure Device (LockeT), is a suture retention device indicated for wound healing by distributing suture tension.